I think you’re asking about Nurtec (rimegepant) and something called “Symbravo.” I’m not aware of a marketed migraine drug named Symbravo. Could you confirm what Symbravo is (a brand name, a generic, or another drug) or share a link? If you meant Nurtec alone, here’s a concise summary of the key clinical trial data.
Nurtec ODT (rimegepant) – what the main trials show
- Indications studied
- Acute treatment of migraine in adults (single-dose, 75 mg).
- Preventive treatment of migraine (75 mg every other day), studied later in development.
- Acute treatment trials (Phase 3: ACHIEVE I and ACHIEVE II)
- Design: randomized, double-blind, placebo-controlled trials of rimegepant 75 mg.
- Primary endpoints: 2-hour pain relief and 2-hour freedom from the most bothersome symptom (MBS).
- Outcomes: Rimegepant 75 mg showed statistically significant improvements vs placebo on the 2-hour endpoints in both trials. Benefits were evident across multiple subgroups (e.g., with/without nausea, different baseline pain levels).
- Safety: Generally well tolerated; adverse events were similar to placebo; common AEs were mild (e.g., nausea, mild GI upset) with no clear signal of hepatic toxicity or cardiovascular risk. No vasoconstrictive concerns (gepants) in these trials.
- Long-term and tolerability
- Open-label extensions and longer-term safety data indicate sustained efficacy with continued use and a favorable safety profile over extended periods.
- Re-administration in same-episode or subsequent episodes has not shown new safety concerns in the extension data.
- Preventive treatment data (rimegepant for migraine prevention)
- Study design: randomized trials of 75 mg every other day vs placebo in adults with frequent migraines.
- Outcomes: Reduction in monthly migraine days (MMD) vs placebo; improvements in patient-reported outcomes and quality of life measures.
- Safety: Overall tolerability similar to placebo; no major new safety signals across the preventive studies; common AEs were mild to moderate and similar to those seen in acute trials.
- Note: Preventive data support a potential role for rimegepant as a preventive option, in addition to its acute-use label, but the preventive labeling and recommendations depend on regulatory approvals in your region.
How these data fit into clinical use
- Nurtec provides a once-per-episode acute option with an onset typically within a few hours, and it has a tolerability profile favorable compared with some older migraine meds.
- For prevention, data suggest a reduction in monthly migraine days with a convenient every-other-day dosing schedule, though clinicians tailor use based on patient history and regulatory labeling in their country.
If you can tell me:
- Do you want acute-treatment data only, preventive data only, or both?
- Are you looking for specific endpoints (e.g., 2-hour pain relief, 2-hour freedom from MBS, responder rates, placebo-adjusted effects), or exact numbers and p-values?
- Do you want data in adults only or include special populations?
I can then provide more targeted summaries or pull out exact figures from the published trials. Also, if you meant a different drug or company product named Symbravo, please share more details so I can address that specifically.